619 filings
Page 8 of 31
8-K
eufi18zp3v8 hctih
8 Nov 17
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
12:00am
8-K
tk8p03
27 Oct 17
Other Events
12:00am
8-K
94w1x9uc z099l
17 Oct 17
TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial
12:00am
8-K
26il95uha2bv yrl2yim
5 Sep 17
TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
12:00am
8-K
wgauvjk 8d4boospzs5
10 Aug 17
Other Events
12:00am
8-K
j8a3vk7d
9 Aug 17
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
12:00am
8-K
3tycwq9vi9ccjcm
1 Aug 17
Global Phase 3 Program Expected to Commence Before End of Q3 2017
12:00am
8-K
y1agxu8dj0korurnl
21 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
q6jup7his1 29wi
16 Jun 17
Other Events
12:00am
EFFECT
tigj zb16a
13 Jun 17
Notice of effectiveness
12:00am
CORRESP
kq49rlmywrsxz vmi
9 Jun 17
Correspondence with SEC
12:00am
8-K
isj 8qc2v
5 Jun 17
Other Events
12:00am
8-K
dmi099sm
24 May 17
TG Therapeutics, Inc. Announces Successful Outcome from Pre-Planned Interim Analysis by Independent DSMB in the UNITY-CLL Phase 3 Trial
12:00am
8-K
yvfqvwt
5 May 17
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2017 Financial Results
12:00am
8-K
bf9w8vv3nbeult745ez
1 May 17
TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months
12:00am